We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

239 hedge funds and large institutions have $1.24B invested in Pacira BioSciences in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 67 increasing their positions, 95 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

374% more call options, than puts

Call options by funds: $3.13M | Put options by funds: $661K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

23% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 30

3% more funds holding

Funds holding: 233 → 239 (+6)

2% more capital invested

Capital invested by funds: $1.21B → $1.24B (+$28.4M)

2.41% less ownership

Funds ownership: 109.17% → 106.76% (-2.4%)

29% less repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 95

Holders
239
Holders Change
+6
Holders Change %
+2.58%
% of All Funds
3.14%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
37
Increased
67
Reduced
95
Closed
30
Calls
$3.13M
Puts
$661K
Net Calls
+$2.47M
Net Calls Change
-$2.36M

Top Buyers

1
DPCM
Doma Perpetual Capital Management
Florida
+$22M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.1M
3
American Century Companies
American Century Companies
Missouri
+$4.81M
4
Morgan Stanley
Morgan Stanley
New York
+$4.73M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$4.16M

Top Sellers

1
PCH
Polar Capital Holdings
United Kingdom
-$21.8M
2
BlackRock
BlackRock
New York
-$11.3M
3
EC
EcoR1 Capital
California
-$10.9M
4
Millennium Management
Millennium Management
New York
-$10.9M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$8.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$189M -$11.3M -459,831 -6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$134M -$5.12M -208,397 -4%
DPCM
3
Doma Perpetual Capital Management
Florida
$69.6M +$22M +897,255 +50%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$55.8M +$291K +11,831 +0.5%
Renaissance Technologies
5
Renaissance Technologies
New York
$55.1M -$6.32M -257,400 -11%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$50M -$7.64M -311,222 -14%
State Street
7
State Street
Massachusetts
$49M -$1.23M -50,047 -3%
Balyasny Asset Management
8
Balyasny Asset Management
Illinois
$48.6M -$6.03M -245,662 -12%
American Century Companies
9
American Century Companies
Missouri
$35.5M +$4.81M +196,000 +17%
Goldman Sachs
10
Goldman Sachs
New York
$33.8M +$26.7K +1,087 +0.1%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$31.3M +$1.79M +72,685 +6%
Morgan Stanley
12
Morgan Stanley
New York
$29.4M +$4.73M +192,726 +20%
UBS Group
13
UBS Group
Switzerland
$22M -$4.27M -174,028 -17%
JGC
14
J. Goldman & Co
New York
$17.2M +$309K +12,576 +2%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$16.8M -$8.16M -332,162 -34%
Charles Schwab
16
Charles Schwab
California
$16.2M +$1.4M +57,194 +10%
Impax Asset Management Group
17
Impax Asset Management Group
United Kingdom
$15.5M +$3.19M +130,000 +28%
Northern Trust
18
Northern Trust
Illinois
$14.8M -$283K -11,507 -2%
Wellington Management Group
19
Wellington Management Group
Massachusetts
$13.6M -$420K -17,087 -3%
Invesco
20
Invesco
Georgia
$13.3M +$934K +38,025 +8%
GS
21
Gagnon Securities
New York
$11.6M +$2M +81,364 +22%
BCM
22
Bridgeway Capital Management
Texas
$11.5M -$382K -15,535 -3%
JP Morgan Chase
23
JP Morgan Chase
New York
$11.2M +$2.31M +94,192 +28%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$10.6M +$10.1M +409,997 New
Deutsche Bank
25
Deutsche Bank
Germany
$9.95M +$298K +12,113 +3%
1
2 3 4 5

PCRX Hedge Fund Activity: Q3 2025 in Review

239 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2025, worth a combined $1.24B — up 2.3% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PCRX positions and 30 closed out — a net gain of 7 holders — while 67 added to existing stakes and 95 trimmed.

The largest buyer was Doma Perpetual Capital Management, adding an estimated $22M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $21.8M sold.

  • 239 institutional investors held Pacira BioSciences (PCRX) as of Q3 2025, up from 233 in Q2 2025.
  • Funds reported $1.24B of Pacira BioSciences stock for Q3 2025, up 2.3% quarter-over-quarter.
  • 37 funds opened new Pacira BioSciences positions in Q3 2025 and 30 closed out, a net change of +7 holders.
  • The largest Pacira BioSciences buyer in Q3 2025 was Doma Perpetual Capital Management, an estimated $22M added.
  • The largest Pacira BioSciences seller in Q3 2025 was Polar Capital Holdings, an estimated $21.8M sold.

Based on aggregated 13F filings for Q3 2025.